Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06031194 | RECRUITING | Central Nervous System Lymphoma

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Sponsor:

Ohio State University Comprehensive Cancer Center

Information provided by (Responsible Party):

Timothy Voorhees

Brief Summary:

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Condition or disease

Central Nervous System Lymphoma

Diffuse Large B-Cell Lymphoma

Intervention/treatment

Non-Interventional Study

Detailed Description:

PRIMARY OBJECTIVES: I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity. OUTLINE: This is an observational study. Participants undergo blood sample collection and have their medical records reviewed on study.

Study Type : OBSERVATIONAL
Estimated Enrollment : 20 participants
Official Title : Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Actual Study Start Date : 2023-05-10
Estimated Primary Completion Date : 2025-09-30
Estimated Study Completion Date : 2025-11-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * \* Adult (age ≥ 18 years at diagnosis)
  • * Diagnosis of DLBCL or PCNSL
  • * Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital.
  • Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m\^2.
  • * Ability to provide informed consent.
Exclusion Criteria
  • * \* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
  • * Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding
  • * Prisoners or incarcerated patients
  • * Total bilirubin \> 5 mg/dL
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Location Details

NCT06031194

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Ohio

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States, 43210